Changes in the Composition of the Human Fecal Microbiome After Bacteriotherapy for Recurrent Clostridium difficile-associated Diarrhea
The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
CDAD is the major known cause of antibiotic-induced diarrhea and colitis, and the disease is thought to result from persistent disruption of commensal gut microbiota.Bacteriotherapy by way of fecal transplantation can be used to treat recurrent CDAD and is thought to re-establish the normal colonic microflora.However, limitations of conventional microbiologic techniques have until recently precluded testing of this idea.In this study we used T-RFLP and 16S rRNA gene sequencing approaches to characterize the bacterial composition of the colonic microflora in a patient suffering from recurrent CDAD, before and after treatment by fecal transplantation from a healthy donor.While the patient's residual colonic microbiota, prior to therapy, was deficient in members of the bacterial divisions-Firmicutes and Bacteriodetes, transplantation had a dramatic impact on the composition of the patient's gut microbiota.By 14 days post transplantation, the fecal bacterial composition of the recipient was highly similar to the donor and was dominated by Bacteroides spp.strains and an uncharacterized butyrate producing bacterium.The change in bacterial composition was accompanied by resolution of the patient's symptoms.The striking similarity of the recipient's and donor's intestinal microbiota following bacteriotherapy suggests that the donor's bacteria quickly occupied their requisite niches, resulting in restoration of both the structure and function of the microbial communities present.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Multiple studies have demonstrated remarkable effectiveness of FMT in cases of recurrent and refractory CDI, which may be attributed to sustained restoration of the normal microbiota after FMT.22,23”
From Fecal microbiota transplantation: Review and update (2019) · cites this paper as [22]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Indeed, studies have demonstrated that patients suffering from recurrent CDI are deficient in phyla of bacteria normally dominant in the colon6,45 (Figure 1).”
From Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook (2015) · cites this paper as [6]
In the citing paper
“Moreover, the restoration of more typical microbial communities, which come to resemble those of the donor post-transplant, persists in a durable fashion after FMT.6, 7”
From Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook (2015) · cites this paper as [6]
In the citing paper
“FMT appears to result in durable engraftment of new species from donor as well as augmentation of species present at only very low levels prior to FMT6.”
From Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook (2015) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An obesity-associated gut microbiome with increased capacity for energy harvest
Turnbaugh, P. J., Ley, R. E., Mahowald, M. A., Magrini, V., Mardis, E. R., & Gordon, J. I. (2006) · Nature · doi:10.1038/nature05414 · Cited by 12,444
Muyzer, G., de Waal, E. C., & Uitterlinden, A. G. (1993) · Applied and Environmental Microbiology · doi:10.1128/aem.59.3.695-700.1993 · Cited by 11,429
Human gut microbes associated with obesity
Ley, R. E., Turnbaugh, P. J., Klein, S., & Gordon, J. I. (2006) · Nature · doi:10.1038/4441022a · Cited by 8,785 · cited 1×
“Many Firmicutes produce butyrate and are postulated to be involved in obesity in humans and murine models.(32,33) Short chain length fatty acids (SCFAs), especially butyrate, have also been shown to play a critical role in maintaining integrity of the colonic epithelium and regulation of the mucosal immune responses.”
BackgroundDiversity of the Human Intestinal Microbial Flora
Eckburg, P. B., Bik, E. M., Bernstein, C. N., Purdom, E., Dethlefsen, L., Sargent, M., Gill, S. R., Nelson, K. E., & Relman, D. A. (2005) · Science · doi:10.1126/science.1110591 · Cited by 7,913
Ecological and Evolutionary Forces Shaping Microbial Diversity in the Human Intestine
Ley, R. E., Peterson, D. A., & Gordon, J. I. (2006) · Cell · doi:10.1016/j.cell.2006.02.017 · Cited by 3,358 · cited 1×
“These bacteria are well-known dominant members of human fecal microbiota,(16) and these phyla are thought to play major ecologic roles in establishment and maintenance of gut homeostasis.(30) A lack of Bacteroides sp.”
BackgroundDevelopment of the Human Infant Intestinal Microbiota
Palmer, C., Bik, E. M., DiGiulio, D. B., Relman, D. A., & Brown, P. O. (2007) · PLoS Biology · doi:10.1371/journal.pbio.0050177 · Cited by 2,877
Edwards, U., Rogall, T., Blöcker, H., Emde, M., & Böttger, E. C. (1989) · Nucleic Acids Research · doi:10.1093/nar/17.19.7843 · Cited by 2,724 · cited 1×
“primers Bact-8F (5’-AGAGTTTGATCCTGGCTCAG-3’) [25] 5′ end-labeled with 6-”
Dethlefsen, L., Huse, S., Sogin, M. L., & Relman, D. A. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060280 · Cited by 2,361
Clostridium difficile— More Difficult Than Ever
Kelly, C. P., & LaMont, J. T. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707500 · Cited by 1,313 · cited 4×
“Unfortunately, the same problem is encountered by others treating this disease.(1) In the studies reported here, we used a molecular approach to gain a better understanding of the bacterial composition of the GI tract in a CDAD patient.”
BackgroundInfluentialDecreased Diversity of the Fecal Microbiome in Recurrent Clostridium difficile–Associated Diarrhea
Chang, J. Y., Antonopoulos, D. A., Kalra, A., Tonelli, A., Khalife, W. T., Schmidt, T. M., & Young, V. B. (2008) · The Journal of Infectious Diseases · doi:10.1086/525047 · Cited by 1,010 · cited 2×
“However, the composition and species richness of intestinal tract microbiota in individuals with CDAD and recurrent CDAD were found to be markedly different from controls.(14) The reestablishment of the normal composition of the intestinal flora has long been hypothesized to be a curative approach for the recurrent CD…”
Background
Cited by
Items 301–400 of 645
Infectious Diarrhea: An Overview
Dickinson, B., & Surawicz, C. M. (2014) · Current Gastroenterology Reports · doi:10.1007/s11894-014-0399-8 · Cited by 45
Microbiome Sequencing Methods for Studying Human Diseases
Davidson, R. M., & Epperson, L. E. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7471-9_5 · Cited by 38
Gut microbiota therapy in gastrointestinal diseases
Ullah, H., Arbab, S., Chang, C., Bibi, S., Muhammad, N., Rehman, S. U., Suleman, S., Ullah, I., Hassan, I. U., Tian, Y., et al. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1514636 · Cited by 42
Papanicolas, L. E., Wang, Y., Choo, J. M., Gordon, D., Wesselingh, S. L., & Rogers, G. B. (2018) · Journal of Microbiological Methods · doi:10.1016/j.mimet.2018.12.001 · Cited by 49
“It is postulated that the efficacy of FMT is dependent on the ability of beneficial commensal bacteria from the donor to proliferate within the recipient (Khoruts et al., 2010; Seekatz et al., 2014; van Nood et al., 2013).”
BackgroundTakyi, E., Nirmalkar, K., Adams, J. B., & Krajmalnik‐Brown, R. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2499580 · Cited by 45
“157,158,165,166 Microbiota transplant therapy (MTT), a treatment derived from FMT, involves more intensive protocols to achieve donor engraftment and clinical benefit.”
‘Omics’ of the mammalian gut – new insights into function
Lamendella, R., VerBerkmoes, N. C., & Jansson, J. K. (2012) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2012.01.016 · Cited by 41
“The normal microbiota can also be disrupted by external factors including antibiotic usage [3], diet [1,4,5], [6,7] and disease [8-13].”
BackgroundSelf-citationMorphine Potentiates Dysbiotic Microbial and Metabolic Shifts in Acute SIV Infection
Sindberg, G. M., Callen, S. E., Banerjee, S., Meng, J., Hale, V. L., Hegde, R., Cheney, P. D., Villinger, F. J., Roy, S., & Buch, S. J. (2018) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-018-9805-6 · Cited by 37
“Dysbiosis can occur as a direct effect of a pathogen outcompeting commensal bacteria, such as in C. difficile (Khoruts et al. 2010) or indirectly as a result of altered host immunity, as in inflammatory bowel disease (Nell et al. 2010).”
BackgroundRecurrent Clostridium difficile infection and the microbiome
Almeida, R., Gerbaba, T. K., & Petrof, E. O. (2015) · Journal of Gastroenterology · doi:10.1007/s00535-015-1099-3 · Cited by 38
“strains became more abundant at later time periods [93].”
Godoy, A. S., Camilo, C. M., Kadowaki, M. A. S., Muniz, H. D. S., Santo, M. C. E., Murakami, M. T., Nascimento, A. S., & Polikarpov, I. (2016) · FEBS Journal · doi:10.1111/febs.13908 · Cited by 36
Fecal microbial transplant for the treatment of pediatric inflammatory bowel disease
Wang, A. Y., Popov, J., & Pai, N. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i47.10304 · Cited by 38
Gut Microbiota, Probiotics, and Sport: From Clinical Evidence to Agonistic Performance
Pane, M., Amoruso, A., Deidda, F., Graziano, T., Allesina, S., & Mogna, L. (2018) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000001058 · Cited by 32
Bascuñana, R. Á. P., Veses, V., & Sheth, C. C. (2021) · Letters in Applied Microbiology · doi:10.1111/lam.13486 · Cited by 42
Metabolic independence drives gut microbial colonization and resilience in health and disease
Watson, A. R., Füssel, J., Veseli, I., DeLongchamp, J. Z., Silva, M., Trigodet, F., Lolans, K., Shaiber, A., Fogarty, E., Runde, J. M., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.02.433653 · Cited by 33
Ishaq, H. M., Yasin, R., Mohammad, I. S., Yang, F., Li, H., Shahzad, M., & Xu, J. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e30494 · Cited by 35
“An imbalance in the gut microbial composition can exacerbate various conditions, including asthma, colitis, Crohn ’ s disease, inflammatory bowel disease, diabetes mellitus, obesity, thyroid cancer and smoking-related disorders [5 – 8].”
BackgroundDranse, H. J., Kelly, M. E. M., & Hudson, B. D. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12327 · Cited by 38
“Faecal transplant of microflora has recently proven to be a valuable tool in the treatment of certain diseases, including colitis caused by Clostridium difficile (Khoruts et al., 2010).”
BackgroundKassam, Z., Lee, C., & Hunt, R. H. (2014) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2014.08.007 · Cited by 34
Gut-Thyroid axis: How gut microbial dysbiosis associated with euthyroid thyroid cancer
Ishaq, H. M., Mohammad, I. S., Hussain, R., Parveen, R., Shirazi, J. H., Yang, F., Shahzad, M., Hayat, K., Li, H., Ihsan, A., et al. (2022) · Journal of Cancer · doi:10.7150/jca.66816 · Cited by 37
“The modulation of gut microbial composition act as a predisposing factor for different disease condition like colitis, inflammatory bowel disease, Crohn's disease, metabolic disorders including diabetes mellitus, asthma, smoking and obesity [4-6].”
Fecal microbiota transplantation: present and future
Cha, R. R., & Sonu, I. S. (2025) · Clinical Endoscopy · doi:10.5946/ce.2024.270 · Cited by 39
“48 49-51 In immunocompetent adults with recurrent CDI, fecal microbiota-based therapies should be considered upon completion of standard-of-care antibiotics over no fecal micro-biota-based therapies.”
Fecal Microbiota Transplantation and Its Potential Therapeutic Uses in Gastrointestinal Disorders
Heath, R. D., Cockerell, C., Mankoo, R., Ibdah, J. A., & Tahan, V. (2017) · Northern Clinics of Istanbul · doi:10.14744/nci.2017.10692 · Cited by 36
“Multiple studies have demonstrated remarkable effectiveness of FMT in cases of recurrent CDI, perhaps due to the observed sustained restoration of the normal microbiota [16, 17].”
BackgroundTariq, R., Hayat, M., Pardi, D. S., & Khanna, S. (2021) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-021-04163-z · Cited by 36
Sofi, A. A., Silverman, A. L., Khuder, S., Garborg, K. K., Westerink, J. M. A., & Nawras, A. T. (2012) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2012.743585 · Cited by 35
“either with laboratory grown [22] or fecal source [22,24].”
BackgroundInfluentialFecal Microbiota Transplantation: Past, Present and Future
Евдокимова, Н. В., & Chernenkaya, T. V. (2019) · Russian Sklifosovsky Journal Emergency Medical Care · doi:10.23934/2223-9022-2019-8-2-160-165 · Cited by 32
Wang, Y., Hunt, A., Danziger, L. H., & Drwiega, E. N. (2024) · Antibiotics · doi:10.3390/antibiotics13050436 · Cited by 32
“…gut microbiome post-transplantation, and that the bacterial contents of the recipient’s stool resemble that of the healthy donor, specifically in the abundance of Bacteroidetes [52,53] This persistent alteration is often referred to as stable engraftment and can last for more than 30 days.”
BackgroundImportant clinical advances in the understanding of Clostridium difficile infection
Pacheco, S. M., & Johnson, S. (2012) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e32835a68d4 · Cited by 32
Duplessis, C. A., You, D. M., Johnson, M. D., & Speziale, A. (2011) · Infection · doi:10.1007/s15010-011-0226-1 · Cited by 31
Fecal microbiota transplantation for recurrent C difficile infection: Ready for prime time?
Agito, M. D., Atreja, A., & Rizk, M. K. (2013) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.80a.12110 · Cited by 29
Liu, J., Lin, H., Cao, M., Tan, L., Lin, A., Xu, W., Wang, H., He, J., Li, Y., Tang, H., et al. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1124256 · Cited by 33
“Moreover, with the deepening of the study, living microbiota are considered to be therapeutic agents for FMT, because the colonization of these microbiota in the intestines of recipients may lead to lasting changes in patients (Khoruts et al., 2010; Seekatz et al., 2014).”
BackgroundMurine models to study Clostridium difficile infection and transmission
Lawley, T. D., & Young, V. B. (2013) · Anaerobe · doi:10.1016/j.anaerobe.2013.09.008 · Cited by 31
“difficile exploits the dysbiotic microbiota to cause recurrent disease in mice and supports the notion that treatments that restore a diverse microbiota and intestinal homeostasis are a valid option for patients with recurrent disease [28,29].”
BackgroundZaborina, O. Y., Zaborin, A., Romanowski, K. S. S., BABROWSKI, T. A., & Alverdy, J. C. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211795703771 · Cited by 29
Future prospect of faecal microbiota transplantation as a potential therapy in asthma
Kang, Y., & Cai, Y. (2017) · Allergologia et Immunopathologia · doi:10.1016/j.aller.2017.04.008 · Cited by 32
Stewart, H. L., Pitta, D., Indugu, N., Vecchiarelli, B., Hennessy, M. L., Engiles, J. B., & Southwood, L. L. (2020) · Equine Veterinary Journal · doi:10.1111/evj.13389 · Cited by 34
Probiotic Bacteria and Enteric Infections
Paton, A., Morona, R., & Paton, J. (2011) · Springer eBooks · doi:10.1007/978-94-007-0386-5 · Cited by 30
Therapeutic Modulation of Gut Microbiota in Functional Bowel Disorders
Lee, H. J., Choi, J., Ryu, H. S., Choi, C. H., Kang, E. H., Park, K. S., Min, Y. W., & Hong, K. S. (2017) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm16124 · Cited by 35
“In addition, the restored gut microbiota became similar to those of the donors, and persisted in a durable fashion after FMT.(106,110,111) Thus, FMT is being applied to several diseases related with dysbiosis other than CDI.”
BackgroundFecal microbiota transplantation for Clostridium difficile infection: benefits and barriers
Lo Vecchio, A., & Cohen, M. B. (2014) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000023 · Cited by 27
“Although fine microbiological evidence supports a durable effect of FMT on fecal microbiota (up to 6 months) [26,27], most studies reported patients’ clinical outcomes for not more than 3 months after transplantation.”
BackgroundResultClostridium difficile Infection
Knight, C. L., & Surawicz, C. M. (2013) · Medical Clinics of North America · doi:10.1016/j.mcna.2013.02.003 · Cited by 34
Faecal microbiota transplantation for Clostridium difficile infection
Dodin, M., & Katz, D. E. (2013) · International Journal of Clinical Practice · doi:10.1111/ijcp.12320 · Cited by 31
Fecal microbiota transplantation: the state of the art
Di Bella, S., Drapeau, C., García-Almodóvar, E., & Petrosillo, N. (2013) · Infectious Disease Reports · doi:10.4081/idr.2013.e13 · Cited by 27
Genome sequencing of Clostridium butyricum DKU-01, isolated from infant feces
Mo, S., Kim, B. S., Yun, S.-J., Lee, J.-J., Yoon, S.-H., & Oh, C. (2015) · Gut Pathogens · doi:10.1186/s13099-015-0055-3 · Cited by 27
“number of livestock species [1].”
Wild immunology: converging on the real world
Babayan, S. A., Allen, J. E., Bradley, J. E., Geuking, M. B., Graham, A. L., Grencis, R. K., Kaufman, J., McCoy, K. D., Paterson, S., Smith, K. G. C., et al. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06251.x · Cited by 37
Machado, A. M. D., & Sommer, M. O. A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100739 · Cited by 32
“The relationship between the host and its resident microbiota can be mutually beneficial and the microbiota has substantial impact on human health, including dietary and nutritional processing, prevention of pathogen invasion and immune system maturation [8–10].”
BackgroundFecal Transplant in Refractory Clostridium difficile Colitis
Kleger, A., Schnell, J., Essig, A., Wagner, M., Bommer, M., Seufferlein, T. T. W., & Härter, G. (2013) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2013.0108 · Cited by 33
Paleomicrobiology: a Snapshot of Ancient Microbes and Approaches to Forensic Microbiology
Rivera-Pérez, J. I., Santiago-Rodríguez, T. M., & Toranzos, G. A. (2016) · Microbiology Spectrum · doi:10.1128/microbiolspec.emf-0006-2015 · Cited by 30
“Sequence analysis of the 16S rRNA gene amplicons from the mummy colon showed that such sequences allowed for the detection of several species of the genus Clostridium that are part of the microbiota of the human colon (69).”
BackgroundBulow, C., Langdon, A. E., Hink, T., Wallace, M. A., Reske, K. A., Patel, S., Sun, X., Seiler, S. M., Jones, S., Kwon, J. H., et al. (2018) · mSphere · doi:10.1128/mspheredirect.00588-18 · Cited by 28
The Hologenome Concept of Evolution: Medical Implications
ROSENBERG, E. B., & Zilber‐Rosenberg, I. (2019) · Rambam Maimonides Medical Journal · doi:10.5041/rmmj.10359 · Cited by 30
The Impact of Regulatory Policies on the Future of Fecal Microbiota Transplantation
Khoruts, A., Hoffmann, D. E., & Palumbo, F. B. (2019) · The Journal of Law Medicine & Ethics · doi:10.1177/1073110519897726 · Cited by 29
Self-citationIntestinal microbiota research from a global perspective
Wallenborn, J. T., & Vonaesch, P. (2022) · Gastroenterology report · doi:10.1093/gastro/goac010 · Cited by 27
“Fecal microbiota transfers (FMT) have also been used especially for refractory Clostridium difficile infections [169, 170].”
Han, S. S., Shannahan, S. E., & Pellish, R. S. (2016) · Journal of Intensive Care Medicine · doi:10.1177/0885066615594344 · Cited by 34
“Clostridium difficile infection is the major cause of antibioticinduced diarrhea and colitis.(28,29) The most frequently implicated antibiotics that increase the risk of CDI include clindamycin, cephalosporins, penicillins, and fluoroquinolones.”
BackgroundMicrobiota-Associated Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Cancer: A Review
Chen, Y., Wu, W., & Wu, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21175999 · Cited by 32
Diagnosis and Management of Clostridium difficile Infection
Korman, T. M. (2015) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0034-1398741 · Cited by 34
Banks, K. C., Giuliano, E. A., Busi, S. B., Reinero, C. R., & Ericsson, A. C. (2020) · Frontiers in Veterinary Science · doi:10.3389/fvets.2020.00558 · Cited by 25
“conjunctival microbiota to the periocular haired skin and distal nose, and (3) compare”
BackgroundMethodDu, H., Song, Z., Zhang, M. H., Nie, Y., & Xu, Y. (2020) · Food Research International · doi:10.1016/j.foodres.2020.109872 · Cited by 25
Gut microbiome–based therapeutics in inflammatory bowel disease
Hu, K. A., & Gubatan, J. M. B. (2023) · Clinical and Translational Discovery · doi:10.1002/ctd2.182 · Cited by 26
The human microbiota associated with overall health
Xu, X., Wang, Z., & Zhang, X. (2013) · Critical Reviews in Biotechnology · doi:10.3109/07388551.2013.819485 · Cited by 29
“Such as, Khoruts et al. (2010) demonstrated after 2 weeks of transplanting the microbial community from a healthy donor to a patient suffering from C. difficile-associated disease (CDAD), the microbiota of the recipient was dramatically changed from a Firmicutes- and Bacteroidetes-deficient…”
BackgroundInfluentialMaurice, C. F., & Turnbaugh, P. J. (2013) · FEMS Microbiology Reviews · doi:10.1111/1574-6976.12022 · Cited by 32
“Notable examples include (1) the ‘fecal transplantation’ of an intact donor gut microbiota to Clostridium difficile patients (Khoruts et al., 2010), (2) the lateral gene transfer of genetic loci for polysaccharide metabolism from algal bacteria to the gut microbiome (Hehemann et al.”
BackgroundFecal transplantation for the treatment of recurrentClostridium difficileinfection
Karadsheh, Z., & Sule, S. S. (2013) · North American Journal of Medical Sciences · doi:10.4103/1947-2714.114163 · Cited by 29
Revealing Complex Ecological Dynamics via Symbolic Regression
Chen, Y., Angulo, M. T., & Liu, Y. (2019) · BioEssays · doi:10.1002/bies.201900069 · Cited by 35
Fecal microbiota transplantation in childhood: past, present, and future
Gu, X., Chen, Z.-H., & Zhang, S. (2022) · World Journal of Pediatrics · doi:10.1007/s12519-022-00655-w · Cited by 26
“1 3 which are appropriate for traditional therapy [5, 6, 9, 20].”
Borody, T. J., Brandt, L. J., Paramsothy, S., & Agrawal, G. (2013) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.13.26 · Cited by 24
Dave, M., Johnson, L. A., Walk, S. T., Young, V. B., Stidham, R. W., Chaudhary, M. N., Funnell, J. A., & Higgins, P. (2011) · Gut · doi:10.1136/gut.2010.224337 · Cited by 25
Lee, B. B., Toh, S.-L., Ryan, S., Simpson, J. M., Clezy, K. R., Bossa, L., Rice, S. A., Marial, O., Weber, G., Kaur, J., et al. (2016) · BMC Urology · doi:10.1186/s12894-016-0136-8 · Cited by 24
Park, J., Shin, E., Hong, H., Shin, H.-J., Cho, Y., Ahn, K.-H., Paek, K., & Lee, Y. (2015) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.1505.05015 · Cited by 28
“Recently, several trials of transfer of microbiomes have produced successful results in animals and humans [19, 20].”
BackgroundResultFecal microbiota transplantation for Clostridium difficile infection in patients with ileal pouches
Lan, N., Ashburn, J. H., & Shen, B. (2017) · Gastroenterology report · doi:10.1093/gastro/gox018 · Cited by 24
Cataldo, M. A., Granata, G., & Petrosillo, N. (2017) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2017.1387535 · Cited by 28
“patients with recurrent CDI is associated with a normalization 420 of the microbial community structure as early as 24 h after the procedure with an increase in the overall microbial diversity, an increase of Bacteroidetes and Firmicutes phyla and a decrease in Proteobacteria in fecal microbiota [66] Importantly, it h…”
BackgroundResultMa, S., Wang, Y., Ji, X., Dong, S., Wang, S., Zhang, S., Deng, F., Chen, J., Lin, B., Khan, B. A., et al. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1364545 · Cited by 27
Spinal cord injury: pathophysiology, possible treatments and the role of the gut microbiota
Pagán-Rivera, L. H., Ocasio-Rivera, S. E., Godoy‐Vitorino, F., & Miranda, J. D. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1490855 · Cited by 25
Bridging Taxonomic and Disciplinary Divides in Infectious Disease
Borer, E. T., Antonovics, J., Kinkel, L. L., Hudson, P. J., Daszak, P., Ferrari, M. J., Garrett, K. A., Parrish, C. R., Read, A. F., & Rizzo, D. M. (2011) · EcoHealth · doi:10.1007/s10393-011-0718-6 · Cited by 23
“Bacteriotherapy is a new and extremely promising manipulation of microbes in humans to control disease (Khoruts et al. 2010).”
BackgroundJiang, Z.-D., Hoang, L. N., Lasco, T. M., Garey, K. W., & DuPont, H. L. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cis1025 · Cited by 23
Brace, C., Gloor, G. B., Ropeleski, M. J., Allen‐Vercoe, E., & Petrof, E. O. (2014) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2014.01.020 · Cited by 23
Aoki, R., Tsuchida, S., Arai, Y., Ohno, K., Nishijima, T., Mawatari, T., Mikami, Y., & Ushida, K. (2016) · Food Science & Nutrition · doi:10.1002/fsn3.344 · Cited by 25
“…bile acids, which partially explains its higher rate of proliferation in the large intestine. induces not only various acute disorders such as diarrhea (Young and Schmidt 2004; Khoruts et al. 2010) but also chronic disorders such as obesity (Turnbaugh et al. 2006, 2009; Vijay-Kumar et al. 2010).”
Bahitham, W., Alghamdi, S., Omer, I., Alsudais, A. S., Hakeem, I., Alghamdi, A., Abualnaja, R., Sanai, F. M., Rosado, A. S., & Sergi, C. M. (2024) · Biomedicines · doi:10.3390/biomedicines12030550 · Cited by 24
Willette, J. A., Pitta, D., Indugu, N., Vecchiarelli, B., Hennessy, M. L., Dobbie, T., & Southwood, L. L. (2021) · BMC Veterinary Research · doi:10.1186/s12917-020-02706-8 · Cited by 26
Biswas, V., Praveen, A., Marisetti, A. L., Sharma, A., Kumar, V., Sahu, S. K., & Tewari, D. (2022) · Dietetics · doi:10.3390/dietetics1030017 · Cited by 29
“This “gut microbiota” is a complicated ecosystem to communicate with one another and with the human to influence vital biological function, such as regulating juvenile growth [23,23], maturation of the immune system, and protection against some infectious agents [24].”
BackgroundReview Article: Gastroenterology and Clostridium difficile Infection: Past, Present, and Future
Kelly, C. R., & Allegretti, J. R. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad644 · Cited by 24
Diverticulitis after Fecal Microbiota Transplant for C. difficile Infection
Mandalia, A. B., Kraft, C. S., & Dhere, T. (2014) · The American Journal of Gastroenterology · doi:10.1038/ajg.2014.350 · Cited by 23
Carlucci, C., Jones, C. S., Oliphant, K., Yen, S., Daigneault, M. C., Carriero, C., Robinson, A. V., Petrof, E. O., Weese, J. S., & Allen‐Vercoe, E. (2019) · Scientific Reports · doi:10.1038/s41598-018-37547-x · Cited by 27
Root-Bernstein, R. S. (2016) · BioEssays · doi:10.1002/bies.201600083 · Cited by 25
“For example, C. difficile infection causes specific alterations in the microbiome that may be responsible for the chronic nature of the infection [112, 113] .”
BackgroundEvaluation of Oxford Nanopore MinION TM Sequencing for 16S rRNA Microbiome CharacterizationPreprint
Ma, X., Stachler, E. N., & Bibby, K. J. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/099960 · Cited by 22
Alverdy, J. C., Gilbert, J. A., DeFazio, J. R., Sadowsky, M. J., Chang, E. B., Morowitz, M. J., & Teitelbaum, D. H. (2013) · Journal of Parenteral and Enteral Nutrition · doi:10.1177/0148607113517904 · Cited by 24
Self-citationAzimirad, M., Jo, Y., Kim, M.-S., Jeong, M., Shahrokh, S., Aghdaei, H. A., Zali, M. R., Lee, S., Yadegar, A., & Shin, J. (2022) · Journal of Inflammation Research · doi:10.2147/jir.s338212 · Cited by 23
Faecal transplantation for the treatment of Clostridium difficile infection: a review
McCune, V. L., Struthers, J. K., & Hawkey, P. M. (2013) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2013.10.009 · Cited by 29
Rooks, M. G., & Garrett, W. S. (2011) · F1000 Biology Reports · doi:10.3410/b3-12 · Cited by 25
“Increasing antibiotic resistance has renewed interest in alternative bacteriotherapy [25] and its success is raising interest in its use for other ailments.”
BackgroundThe Present Status of Fecal Microbiota Transplantation and Its Value in the Elderly
Cheng, Y., & Fischer, M. (2017) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-017-0143-1 · Cited by 23
“difficile and subsequent toxin production [11, 12].”
The gut microbiome: what every gastroenterologist needs to know
Mullish, B. H., Quraishi, M. N., Segal, J. P., Ianiro, G., & Iqbal, T. H. (2020) · Frontline Gastroenterology · doi:10.1136/flgastro-2019-101376 · Cited by 25
Vindigni, S. M., Broussard, E. K., & Surawicz, C. M. (2013) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2013.832501 · Cited by 24
Methodological Strategies in Microbiome Research and their Explanatory Implications
O’Malley, M. A., & Skillings, D. (2018) · Perspectives on Science · doi:10.1162/posc_a_00274 · Cited by 30
Palmer, R. (2011) · Nature Medicine · doi:10.1038/nm0211-150 · Cited by 26
Edelstein, C. A., Kassam, Z., Daw, J. R., Smith, M. B., & Kelly, C. R. (2015) · Clinical Research and Regulatory Affairs · doi:10.3109/10601333.2015.1046602 · Cited by 24
Faecal Microbiota Analysis of Piglets During Lactation
Nowland, T. L., Torok, V. A., Low, W. Y., BARTON, M. D., Plush, K. J., & Kirkwood, R. N. (2020) · Animals · doi:10.3390/ani10050762 · Cited by 22
“FMT has been demonstrated to be an effective tool in the treatment of Clostridium difficile infections in humans [9], with studies showing that FMT changes the microbiota of the sick recipient to become more similar to that of the faeces they were treated with [39].”
BackgroundWongkuna, S., Ambat, A., Ghimire, S., Mattiello, S. P., Maji, A., Kumar, R., Antony, L., Chankhamhaengdecha, S., Janvilisri, T., Nelson, E. A., et al. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.01621-23 · Cited by 23
“The pathogen exclusion ability of the gut 303 microbiota has been used to suppress Clostridium difficile infection in humans [7] and to exclude 304”
BackgroundMethodFecal Microbiota Transplant to Treat Recurrent Clostridium difficile Infections
Boyle, M. L., Ruth-Sahd, L. A., & Zhou, Z. (2015) · Critical Care Nurse · doi:10.4037/ccn2015356 · Cited by 25
Drug Discovery for Targeting Drug Resistant Bacteria
Valsamatzi-Panagiotou, A., Popova, K. B., & Prof. Robert Penchovsky, D. R. N. (2020) · Sustainable agriculture reviews · doi:10.1007/978-3-030-53024-2_9 · Cited by 20
Woloszynek, S., Pastor, S. J., Mell, J. C., Nandi, N., Sokhansanj, B. A., & ROSEN, G. L. (2016) · International review of cytology · doi:10.1016/bs.ircmb.2016.01.003 · Cited by 26
Evolving Ecosystems: Inheritance and Selection in the Light of the Microbiome
Sandoval‐Motta, S., Aldana, M., & Frank, A. (2017) · Archives of Medical Research · doi:10.1016/j.arcmed.2018.01.002 · Cited by 21
Wang, Y., Wang, S., Bouillaut, L., Li, C., Duan, Z., Zhang, K., Ju, X., Tzipori, S. R., Sonenshein, A. L., & Sun, X. (2018) · Infection and Immunity · doi:10.1128/iai.00489-18 · Cited by 20
Lam, W. C., Zhao, C., Ma, W. J., & Yao, L. (2019) · Gastroenterology Research and Practice · doi:10.1155/2019/1287493 · Cited by 20
Veterinary ocular microbiome: Lessons learned beyond the culture
Banks, K. C., Ericsson, A. C., Reinero, C. R., & Giuliano, E. A. (2019) · Veterinary Ophthalmology · doi:10.1111/vop.12676 · Cited by 25
Björkqvist, O., Rangel, I., Serrander, L., Magnusson, C., Halfvarson, J., Norén, T., & Jungeström, M. B. (2021) · PLoS ONE · doi:10.1371/journal.pone.0249861 · Cited by 20
Fecal microbiota transplantation for recurrent Clostridium difficile infection in children
Chen, B., Avinashi, V., & Dobson, S. (2017) · Journal of Infection · doi:10.1016/s0163-4453(17)30202-5 · Cited by 19
The role of the microbiota in ageing: current state and perspectives
Lynch, D. B., Jeffery, I. B., & O’Toole, P. W. (2015) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1293 · Cited by 23
Fecal microbiota transplantation for Clostridium difficile infection: back to the future
Borgia, G., Maraolo, A. E., Foggia, M., Buonomo, A. R., & Gentile, I. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1045872 · Cited by 22
“FMT quickly restores the normal ‘donor-like’ composition of intestinal microbiota dominated by Bacteroidetes and Firmicutes and containing reduced proportions of g-Proteobacteria [61].”
Background
Metadata
- Authors
- Khoruts, A., Dicksved, J., Jansson, J. K., & Sadowsky, M. J.
- Affiliations
- University of Minnesota (US)
- Swedish University of Agricultural Sciences (SE)
- Lawrence Berkeley National Laboratory (US)
- Corresponding author
- Khoruts, Alexander
- Venue
- Journal of Clinical Gastroenterology
- Published
- 2010-05
- Volume
- 44
- Issue
- 5
- Pages
- 354-360
- ISSN
- 0192-0790 (ISSN-L)
- OpenAlex
- W2095040140
- Cited by
- 649
- References
- 37
- Citations by year
- 2026: 6 · 2025: 15 · 2024: 22 · 2023: 14 · 2022: 13 · 2021: 26 · 2020: 29 · 2019: 41 · 2018: 49 · 2017: 49 · 2016: 53 · 2015: 49 · 2014: 69 · 2013: 88 · 2012: 47
- FWCI
- 44.22
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- Clostridium difficile-associated diarrhea, fecal microbiota transplantation, gut microbiota composition, colonic microbiota, Firmicutes, Bacteroidetes, Bacteroides, butyrate-producing bacteria, antibiotic-associated diarrhea
- MeSH terms
- Enterocolitis, Pseudomembranous, Feces, Female, Follow-Up Studies, Humans, Middle Aged, Polymorphism, Restriction Fragment Length, RNA, Ribosomal, 16S, Clostridioides difficile, Sequence Analysis, RNA, Metagenome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.